*Based on BIOSOLVE-II, -II/-III and -IV, for patient populations see study details;
1. According to the Magnesium 2,000 program; 2. Torzewski J. Safety and performance of Magmaris at 24-month follow-up of BIOSOLVE-IV. Presented at: eEuroPCR; 2021; virtual congress. ClinicalTrials.gov: NCT02817802; Target Lesion Failure (TLF) defined as a composite of Cardiac Death, Target-Vessel Myocardial Infarction (TV-MI), emergent Coronary Artery Bypass Grafting (CABG) and Clinically-Driven Target Lesion Revascularization (CD-TLR).
Magmaris is a trademark or registered trademark of the BIOTRONIK Group of Companies.
Magmaris is currently not available in the US.
© 2021 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.